Amlexanox inhibits production of type I interferon and suppresses B cell differentiation <i>in vitro</i>: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseases
Our findings demonstrate inhibitory effects of amlexanox on type I IFN production and B cell differentiation in primary human cells. Inhibition of TBK1 could potentially be a therapeutic option for the treatment of type I IFN-driven systemic inflammatory diseases.
Authors
- Marjan A. Versnel (ORCID: https://orcid.org/0000-0003-0245-5386)
- Jasper Rip (ORCID: https://orcid.org/0000-0001-5780-9271)
- Zana Brkić (ORCID: https://orcid.org/0000-0002-5454-3495)
- Cornelia G van Helden-Meeuwsen (ORCID: https://orcid.org/0009-0009-6393-7347)
- Sylvia Kamphuis (ORCID: https://orcid.org/0000-0002-1964-352X)
- Sander J van Tilburg (ORCID: https://orcid.org/0000-0003-3983-9797)
- M. J. Wahadat (ORCID: https://orcid.org/0000-0003-3961-1274)
- Thierry P. P. van den Bosch
- Merijn Braams (ORCID: https://orcid.org/0000-0001-8013-7442)
- Albin Björk
- Maria Sánchez-Blázquez
Institutions
- Erasmus MC (NL)
- Karolinska Institutet (SE)
- Erasmus MC - Sophia Children’s Hospital (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- RMD Open
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/rmdopen-2024-005351
- Citations
- 2
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- Åke Wiberg Stiftelse
- Tore Nilsons Stiftelse för Medicinsk Forskning
- Stiftelsen Lars Hiertas Minne
- Magnus Bergvalls Stiftelse
- Stiftelsen Konung Gustaf V:s 80-årsfond
- Stiftelsen Professor Nanna Svartz Fond
- Servier
- Stockholm läns landsting
- Foundation for Research in Rheumatology